Allergan's behavior here is unacceptable, and if other drug companies follow its lead, the problem is only going to get worse.
On the recordOctober 16, 2017
Source
congress.govEditor's note · Context
Hassan criticizes Allergan's actions and warns of broader implications for drug pricing.
Share
More from Maggie Hassan
Jun 23, 2026
I’m pleased to see this important measure advance with strong bipartisan support, and I will continue to work to help people with disabilities get the care that they need and deserve.
Jun 23, 2026
No one should be denied a life-saving organ transplant just because they have a disability.
Jun 19, 2026
For too long, Big Pharma has been abusing the patent process to block generic competition and keep drug prices for patients artificially high.
Jun 25, 2026
Your actions to provide the new weight-loss drug Retatrutide to one well-connected individual come as the Trump Administration has driven prescription drug costs for Americans through the roof.





